What is the significance of Germany as the first EU country to launch Novo Nordisk's Wegovy pill?

Germany is described as 'a key European launch market for innovative medicines and the biggest pharmaceutical market in the European Union', making it the first country in the 27-member EU bloc where Novo Nordisk has launched the Wegovy pill — a strategic milestone for the company's oral obesity treatment rollout across Europe.

How does Novo Nordisk's Wegovy pill compare to Eli Lilly's Foundayo in terms of EU regulatory status and market presence as of the time of this news?

As of the news, Novo Nordisk's Wegovy pill had received a positive recommendation from the European Medicines Agency in May and formal approval from the European Commission in July, clearing it for use across the EU; in contrast, Lilly's Foundayo was 'currently under regulatory review in more than 40 markets' with a full rollout across major markets expected only in 2027, and it had not yet received EU approval.

Novo Nordisk launches Wegovy weight-loss pill in Germany

Sep 1, 2026

Novo Nordisk launched its oral Wegovy weight-loss pill in Germany following EU approval, intensifying competition with Eli Lilly in the expanding GLP-1 market. This semaglutide-based treatment targets a sector projected to exceed $100 billion annually by 2030.

reuters

2026-02-25

Novo Nordisk Taps Start-Up for New Oral Weight-Loss Drugs

2026-04-13

Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development

2026-04-23

Novo Nordisk's Oral GLP-1 Drug Meets Primary Goal in Late-Stage Diabetes Study

2026-05-05

Novo Nordisk's first-quarter profit beats forecasts

2026-05-26

Global Firms Bring More Work In-House at India Hubs on AI Boost